Patents by Inventor Baochun Zhang

Baochun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220362296
    Abstract: The disclosure provides immunogenic cells expressing LMP1, and use thereof in activating T cells and treating cancer. Also provided are methods of producing the immunogenic cells.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 17, 2022
    Inventors: Baochun Zhang, IL-Kyu Choi, Zhe Wang
  • Patent number: 11369635
    Abstract: The disclosure provides immunogenic cells expressing LMP1, and use thereof in activating T cells and treating cancer. Also provided are methods of producing the immunogenic cells.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: June 28, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Baochun Zhang, Il-Kyu Choi, Zhe Wang
  • Publication number: 20190192572
    Abstract: The disclosure provides immunogenic cells expressing LMP1, and use thereof in activating T cells and treating cancer. Also provided are methods of producing the immunogenic cells.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 27, 2019
    Inventors: Baochun Zhang, IL-Kyu Choi, Zhe Wang
  • Publication number: 20180084766
    Abstract: Provided herein are rapid, reliable methods for generating mice (or other species) that develop tumors of known genotype with respect to two or more mutated, tumor-associated genes using blastocyst complementation.
    Type: Application
    Filed: April 7, 2016
    Publication date: March 29, 2018
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Frederick W. Alt, Feilong Meng, Zhaoqing Ba, Monica Gostissa, Baochun Zhang, Pei-Chi Wei, Bjoern Schwer
  • Publication number: 20060117399
    Abstract: This invention develops the first mouse model for human lymphomas with mutations in the NF-KB2 gene that can be used for the study of the pathogenesis of this subset of lymphomas and for the development and testing of therapeutic and prevention drugs. The mice develop B- and T-cell lymphomas with extensive metastases in the liver, lung and kidneys, and can be used as an animal model for the development and testing of therapeutic/prevention drugs that target this group of human lymphoma patients.
    Type: Application
    Filed: November 29, 2005
    Publication date: June 1, 2006
    Applicant: Medical University
    Inventors: Han-Fei Ding, Baochun Zhang